Trade HALO anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Halozyme Therapeutics, Inc. (HALO) is trading at US$104.96, down 1.83% today as of Aug 28, 11:17 EDT. The company has a market capitalisation of US$12.28B. Over the past 52 weeks, HALO has traded between US$61.23 and US$109.66. On Syfe you can trade HALO with $0 commission and add it to your watchlist.
| Previous close | US$106.92 |
|---|---|
| Market cap | US$12.28B |
| P/E ratio | 10.89 |
| 52-week range | US$61.23 – US$109.66 |
| Volume | 1.36M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Year: 2004
Halozyme Therapeutics, Inc. (HALO) stock is trading at US$104.96, -1.83% from the previous close of US$106.92.
The market cap for Halozyme Therapeutics, Inc. (HALO) stock is approximately US$12.28B.
The price-to-earnings ratio for Halozyme Therapeutics, Inc. (HALO) is 10.89, based on the latest reported earnings.
The 52-week high for Halozyme Therapeutics, Inc. (HALO) stock is US$109.66.
The 52-week low for Halozyme Therapeutics, Inc. (HALO) stock is US$61.23.
Halozyme Therapeutics, Inc. (HALO) does not currently pay a dividend.
Stay on top of HALO
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
